These innovative agents represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://jayfend229821.blogrelation.com/45637132/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide